GOLGA3

Across TCGA pan-cancer cohorts, GOLGA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GOLGA3 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GOLGA3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLGA3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where GOLGA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.583	0.922	<.001	68	view →
PDAC	DFS	Tertile	II,III,IV	0.848	0.545	.023	10	view →
LUAD	OS	Quartile	III,IV	0.931	0.391	.026	4	view →
LSCC	DFS	Quartile	III,IV	0.579	1.000	.042	2	view →
HNSC	DFS	Tertile	III,IV	1.000	0.925	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GOLGA3–CCRCC (DFS)

Open the CCRCC breakdown →